Article
New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Seminars in thrombosis and hemostasis - 1 Sept 2010
Köse Ozlem, Zimmerhackl Lothar-Bernd, Jungraithmayr Therese, Mache Christoph, Nürnberger Jens
Abstract excerpt
Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and renal impairment. Often HUS is triggered by Shiga-like toxin- producing ESCHERICHIA COLI. Less common is atypical HUS (aHUS), which is caused by defective complement control. aHUS is associated with mutations in genes encoding complement regulatory proteins in ~50% of patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.